<h3><strong><span style="font-size:13pt;font-family:Arial,sans-serif;">Stock Analysis for Albert David Limited</span></strong><strong><span style="font-size:13pt;font-family:Arial,sans-serif;"><br></span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp; &nbsp;&nbsp;</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp; &nbsp;&nbsp;</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Company Name:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Albert David Limited</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;</span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Ticker Symbol:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;ALBERTDAVD (NSE)</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;</span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Date of Analysis:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;April 20, 2025</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;</span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Sector</span></strong><strong><span style="color:#434343;font-size:13.999999999999998pt;font-family:Arial,sans-serif;">:</span></strong><span style="color:#434343;font-size:13.999999999999998pt;font-family:Arial,sans-serif;">-</span><span style="font-size:11pt;font-family:Arial,sans-serif;">Healthcare &amp; Biotech</span></h3>
<h4><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">1. Ye company kya hai aur kya karti hai?</span></strong></h4>
<p><span style="font-size:11pt;font-family:Arial,sans-serif;">Albert David Limited ek mid-sized pharmaceutical company hai, jo formulations, active pharmaceutical ingredients (APIs), aur intravenous (IV) fluids banati aur market karti hai. Iske key products mein anesthetics, anti-infectives, aur specialized IV fluids (like amino acid infusions) shamil hain, jo hospitals, clinics, aur retail pharmacies mein use hote hain. Company ka focus affordable healthcare solutions pe hai, with a strong presence in East India aur growing exports. Simple bolo toh, Albert David medicines aur IV fluids banata hai jo healthcare mein critical hain, especially budget-conscious markets ke liye.</span></p>
<p><span style="font-size:11pt;font-family:Arial,sans-serif;">Albert David ka role pharmaceutical sector mein hai, jahan ye India ke increasing healthcare demand aur export markets se faida uthata hai. Lekin regulatory pressures (DCGI, NPPA), pricing controls, aur competition se risks hain, jo margins ko impact kar sakte hain. India ka pharma sector 2025-2030 tak 8-10% CAGR se grow karne ka estimate hai, driven by rising healthcare spending aur generic drug demand.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kis Industry Mein Hai?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Albert David pharmaceutical industry mein hai, jo healthcare, generics, aur specialty drugs se linked hai. India ka pharma sector 8-10% annually grow karne ka projection hai, driven by domestic demand (aging population, chronic diseases) aur exports (US, Africa, ASEAN). Lekin strict regulations, price caps, aur global competition (e.g., Chinese APIs) challenges hain. Ye ek stable lekin competitive industry hai&mdash;demand consistent, lekin margins tight. Jhunjhunwala aisi companies pasand karta jo regulations navigate kar sakein, toh financials dekhte hain.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kaise Paise Kamati Hai?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Albert David teen primary tareeke se paise kamati hai:</span></p>
<ul>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Formulations Sales:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Branded generics aur prescription drugs ki domestic sales, especially East India mein.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">IV Fluids:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Specialized IV fluids (e.g., amino acid infusions) ki sales, hospitals aur critical care ke liye.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Exports:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;APIs aur formulations ka export, primarily emerging markets mein.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><span style="font-size:11pt;font-family:Arial,sans-serif;">Uski income sales volumes, pricing power, aur export orders pe depend karti hai&mdash;high demand mein zyada revenue, regulatory hurdles ya price controls mein kam. Ye ek healthcare provider jaisa hai&mdash;demand stable, lekin regulations aur competition se pressure. Jhunjhunwala healthcare bets pasand karta&mdash;kya ye fit hai?</span></p>
    </li>
</ul>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kahan Kaam Karti Hai?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Headquarters Kolkata mein hai, aur manufacturing plants West Bengal aur Uttar Pradesh mein hain. Sales network pan-India hai, with a strong foothold in East India. Export markets mein Africa, ASEAN, aur Latin America shamil hain, contributing ~20-25% revenue. Domestic focus India ke healthcare needs pe hai, jabki exports risk diversification dete hain. Regional strength aur export reach strategic edge deta hai, lekin regulatory changes ya currency fluctuations risk la sakte hain. Jhunjhunwala India-centric growth pe daav lagata tha&mdash;kya ye export mix aapko solid lagta hai?</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Guide&apos;s Explanation:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Albert David pharma sector ka niche player hai, India ke healthcare boom aur export potential ke saath. High ROE aur low debt se future promising hai, lekin EPS decline aur regulations risk hain. Jhunjhunwala ko aisi undervalued, stable companies pasand thi&mdash;kya aap isse portfolio mein dekhte ho? EPS aur cash flow pe dhyan dena hoga.</span></p>
<h4><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">2. Kya ise special banata hai?</span></strong></h4>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kyun Alag Hai?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Albert David ke paas unique strengths hain:</span></p>
<ul>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Niche Focus:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Specialized IV fluids aur affordable generics mein strong presence, especially in East India.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Low Debt:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Debt-to-equity 0.01, almost debt-free, financial stability deta hai.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">High Profitability:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;ROE 19.7%, ROIC 19.6%, aur net profit growth 108.5% industry-leading hain.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Promoter Confidence:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;62.24% promoter holding (recent 0.11% increase) strong commitment dikhata hai.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><span style="font-size:11pt;font-family:Arial,sans-serif;">High OCF growth (332.7%) aur interest coverage 325.1 financial robustness dikhate hain. Ye ek lean, profitable machine jaisa hai. Lekin negative EPS growth (-38.9%) aur small market cap (₹486.1 crore) scale ko limit karte hain.</span></p>
    </li>
</ul>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Ye Advantage Kab Tak Chalega?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Ye edge 5-7 saal tak chal sakta hai, jab tak healthcare demand badhta hai aur Albert David pricing power aur export markets maintain karta hai. Lekin stricter regulations, generic competition, aur larger players (e.g., Sun Pharma, Cipla) long-term moat ko challenge kar sakte hain agar company scale ya innovation mein invest na kare. 5-7 saal ka runway decent hai, lekin forever nahi. Jhunjhunwala lasting moats pasand karta&mdash;Albert David ka survival regulatory compliance aur product differentiation pe depend karta hai. Risk regulatory shocks se hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kaise Pata Ye Real Hai?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">108.5% net profit growth, 332.7% OCF growth, aur Piotroski Score 6 strong financial health dikhate hain. 62.24% promoter holding confidence deta hai. Albert David ka niche market share aur export orders demand confirm karte hain. Ye numbers solid report card jaise hain&mdash;B+ grade! Lekin negative EPS growth (-38.9%) aur 51.44% fall from 52-week high consistency pe sawal uthate hain. Jhunjhunwala undervalued gems dhundta tha&mdash;kya ye sustainable hai, ye check karenge.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Guide&apos;s Explanation:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Albert David ka moat niche products, low debt, aur promoter backing pe hai, jaise ek chhota lekin efficient hospital. Growth potential hai, lekin EPS decline aur regulatory risks se caution chahiye. Jhunjhunwala poochta: kya ye pricing pressures handle karega? Aap kya sochte ho?</span></p>
<h4><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">3. Company ko kaun chalata hai?</span></strong></h4>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Leader Kaun Hai?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">A. K. Kothari Executive Chairman hai, with decades of experience in pharmaceuticals aur business strategy. Umesh Mukhopadhyay Managing Director hai, focusing on operations aur market expansion. Board mein Kothari family members aur independent directors (like Prabhawati Devi Kothari, Anand Vardhan Kothari) hain, covering governance, finance, aur compliance. Leadership team experienced hai, pharma regulations aur competitive landscape navigate karne ke liye.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Paise Kaise Handle Karte Hain?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Debt-to-equity 0.01 hai, industry mein negligible, showing minimal leverage. Operating cash flow ₹45.5 crore aur 332.7% YoY growth exceptional hai, net cash flow ₹4 crore positive hai, showing decent liquidity. Dividend yield 1.2% moderate hai, payout ratio 16.2% ke saath, indicating reinvestment focus. Interest coverage 325.1 industry-leading hai, debt servicing mein koi issue nahi. Low debt aur high OCF stability dete hain, lekin negative EPS growth clarity mangta hai. Jhunjhunwala cash-positive firms pasand karta&mdash;ye mostly fit hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kya Chhote Investors Jaise Humari Parwah Hai?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">62.24% promoter holding (recent 0.11% increase) strong alignment dikhata hai, retail investors ke interests ke saath. Kothari family ka reputation trust deta hai, lekin small market cap (₹486.1 crore) institutional interest kam kar sakta hai. Retail investors ke liye transparency (quarterly results, SEBI filings) decent hai. Jhunjhunwala high promoter stakes pasand karta&mdash;ye positive hai, lekin EPS decline retail confidence pe thoda asar daal sakta hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kya Unpe Trust Kar Sakte Hain?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Koi major scandals nahi, aur Kothari family ka track record clean hai. Piotroski Score 6 aur OPM 11.2% governance aur efficiency dikhate hain. A. K. Kothari aur Umesh Mukhopadhyay ka leadership trust badhate hain. Lekin negative EPS growth aur price fall alignment concerns raise karte hain. Jhunjhunwala experienced management pe bharosa karta&mdash;kya ye aapko confident karta hai?</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Guide&apos;s Explanation:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Leadership solid hai, high promoter holding ke saath. Lekin negative EPS growth aur price fall concerns hain. Jhunjhunwala approve karta agar EPS recover ho&mdash;koi concern hai?</span></p>
<h4><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">4. Company ki money situation kaisi hai?</span></strong></h4>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Revenue Growth:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Rev. Growth YoY 17.7% strong hai, lekin industry median se neeche. Net profit growth 108.5% exceptional hai. Revenue growth shayad domestic demand aur export orders se ho.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Revenue Growth:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Shayad healthcare spending ya new product launches se hua ho. Risk revenue growth slow hone ka hai.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Stock Kaise Manage Karein:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Q4 FY25 results (May 2025) monitor karo ki revenue growth 15%+ rahta hai. Agar growth slow hota hai (&lt;10%), exposure kam karo. Healthcare policy changes check karo.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Earnings Per Share (EPS):</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">EPS ₹70.9 TTM, -38.9% growth, negative hai. Negative EPS growth shayad one-time costs ya pricing pressures se ho.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Negative EPS Growth:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Shayad regulatory costs, R&amp;D expenses, ya margin compression se hua ho. Risk EPS recovery na hone ka hai.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Stock Kaise Manage Karein:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Q4 FY25 mein EPS growth track karo. Agar positive ho ya -10% tak recover kare, hold karo. Sustained decline ho toh thesis reassess karo.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Cash Flow:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">OCF ₹45.5 crore, 332.7% YoY growth, industry-leading. Net cash flow ₹4 crore positive hai. Strong OCF growth core operations se healthy cash generation dikhata hai, net cash flow stable hai.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Strong OCF Growth:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Shayad improved collections ya cost efficiencies se hua ho. Risk OCF slow hone ka hai.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Stock Kaise Manage Karein:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Q4 FY25 mein OCF track karo, dekho ₹40 crore+ rahta hai ya net cash stable rahta hai. Balance sheet mein working capital check karo. OCF strong rahe toh hold karo. Net cash negative ho toh partial stakes becho.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Return on Invested Capital (ROIC):</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">ROIC 19.6%, industry-leading. High ROIC capital efficiency dikhata hai.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for High ROIC:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;High margins aur low capital base se ho sakta hai. Risk regulatory pressures se hai.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Stock Kaise Manage Karein:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Product margins aur regulatory compliance monitor karo.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Debt:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Debt-to-equity 0.01, negligible. Interest coverage 325.1 exceptional hai. Low debt financial stability deta hai, no servicing concerns.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for High Interest Coverage:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Minimal debt aur strong profits se ho sakta hai. Risk nahi hai.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Stock Kaise Manage Karein:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Debt metrics stable rakhne ke liye monitor karo.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Profit Margin:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">OPM 11.2%, industry mein low. Low margins pricing pressures ya high input costs se ho sakte hain.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Low OPM:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Shayad API cost increases ya price caps se ho. Risk margins girne ka hai.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Stock Kaise Manage Karein:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Cost control aur pricing trends track karo.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Assets vs. Liabilities:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Current assets ₹371.6 crore, liabilities ₹99 crore&mdash;current ratio ~3.75, strong liquidity dikhata hai. Moderate assets scale limit karte hain. Risk minimal hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Dividends:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Dividend yield 1.2%, payout ratio 16.2%. Moderate yield income investors ke liye limited hai, lekin reinvestment focus dikhata hai.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kya Ye Sach Mein Reinvesting Hai?:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Payout ratio dikhata hai profits growth projects (e.g., R&amp;D, export expansion) mein ja rahe hain.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Balance Sheet:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Capex spending dekho.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Cash Flow Statement:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Investing activities check karo.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Management Disclosures:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Strategic plans padho.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Low Dividend Yield:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Growth focus aur R&amp;D needs ke liye. Risk reinvestment na hone ka hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Guide&apos;s Explanation:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Finances mixed hain&mdash;strong profit growth, OCF, low debt. Lekin negative EPS growth aur low OPM concerns hain. Jhunjhunwala good (cash flow, valuation) aur bad (EPS, margins) balance karta&mdash;ye mix worry karta hai?</span></p>
<h4><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">5. Kya stock sasta hai?</span></strong></h4>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Current Stock Price:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">₹851.7, 51.44% fall from 52-week high.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Uski Asli Value Kya Hai?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">DCF se intrinsic value ₹1,611.7 hai, price to IV distance -47.2% (stock 47.2% below worth). Undervalued hai. 47.2% discount jaise ₹1,611 ka item ₹851.7 mein khareedna&mdash;bargain hai! 51.44% fall dip ka mauka deta hai. Risk market mispricing ka hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">P/E Ratio:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">12, industry median se neeche. Low P/E earning ke liye kam pay dikhata hai&mdash;sasta hai. Jhunjhunwala P/E 15 se neeche pasand karta&mdash;green light. Risk EPS decline ka hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">P/B Ratio:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">1.2, industry mein low. P/B 1.2 value play hai, lekin negative EPS growth asset use ka concern hai.&nbsp;</span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Low P/B:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Market undervaluation ya EPS issues se ho sakta hai. Risk earnings recovery na hone ka hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Comparison:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Sun Pharma ka P/E 30+ hai, zyada lekin larger scale ke saath. Albert David ka lower P/E better value deta hai, lekin EPS risks zyada. Stable players se sasta&mdash;Jhunjhunwala value play dekhta, lekin stability matter karti hai. Risk volatility ka hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Dip Pe Zyada Clarity Chahiye-Koi Rule Ya Formula Hai?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Dip ka matlab lower price pe khareedna, margin of safety ke liye.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Dip Kyun Wait Karein?:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;₹851.7 pe undervaluation attractive hai. ₹750-800 pe dip se discount ~50-53% ho jata hai&mdash;better entry point. Market correction risk kam karta hai.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Rules Ya Formulas:</span></strong></p>
<ul>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Percentage Decline:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;5-10% drop target karo (5% of ₹851.7 = ₹809.1, 10% = ₹766.5). ₹750-800 align karta hai.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Support Levels:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Historical levels dekho (NSE charts). ₹750 past support ho toh logical hai.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Valuation-Based:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;P/E 10 ya P/B 1 ke paas khareedo. ₹750 pe P/E ~10.6 (EPS ₹70.9) hota hai&mdash;value badhta hai.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Market Correction:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Sensex 3-5% gire toh pharma stocks follow karte hain.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Practical Steps:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Platforms (Zerodha) pe ₹750-800 ke alerts set karo. Volume aur regulatory news monitor karo&mdash;weak Q4 results dip trigger kar sakte hain. Limit orders use karo.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Koi Fixed Rule Nahi:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;₹750-800 judgment hai, Jhunjhunwala 10-15% corrections ka wait karta tha.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Risk:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Wait karne se gains miss ho sakte hain agar stock ₹1,000+ jata hai. Chhoti position abhi khareedo, dips pe add karo.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Price Fall:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Negative EPS growth, market sell-off, ya regulatory concerns se confidence dabaya ho sakta hai. ₹750-800 pe khareedna value investing se align karta hai. Risk fall ka reason check karne ka hai.</span></p>
    </li>
</ul>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Guide&apos;s Explanation:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Stock sasta lagta hai&mdash;IV discount aur low P/E ke saath. 51.44% fall caution hai&mdash;Jhunjhunwala dip ka wait karta. Ye valuation excite karta hai? EPS decline aur fall ke reasons pe dhyan do.</span></p>
<h4><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">6. Kya company future mein grow kar sakti hai?</span></strong></h4>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kya Madad Karega?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">India ka healthcare demand 2025-2030 tak 8-10% grow karega, jo drug consumption ko boost kar sakta hai. Stable pricing aur export growth revenue badha sakte hain. New product launches (e.g., specialty generics) margins improve kar sakte hain. Government healthcare schemes (e.g., Ayushman Bharat) favorable hain. Zyada sales aur export orders matlab bank mein zyada cash&mdash;bada potential. Healthcare demand India ke growth story se fit hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Good Trends:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Pharma sector India mein stable demand deta hai, chronic diseases aur export markets se driven. Albert David ka niche IV fluids portfolio aur export presence long-term growth support karte hain. R&amp;D aur export expansion initiatives sales boost kar sakte hain. Industry growth tailwind hai&mdash;Jhunjhunwala India ke healthcare rise pe sawari karta. Albert David ka low debt aur high ROE help karte hain.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Risks:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Regulatory price caps revenue ko hurt kar sakte hain. Generic competition margins ko impact kar sakta hai. API cost spikes production costs badha sakte hain. Global slowdown export demand ko kam kar sakta hai. Risks real hain&mdash;regulations aur competition hurt kar sakte hain. Jhunjhunwala growth aur caution balance karta.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Risks:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Price caps NPPA policies se ho sakte hain. Competition larger players se hai. API costs global supply chains se hain.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Future Growth:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Agar pricing stable rahe aur exports badhein, toh 8-10% annual growth estimate hai.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Annual Growth Calculate Karne Ka Formula:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;CAGR use karo. Past data (17.7% revenue, 108.5% profit growth) se revenue project karo, constraints (regulations, costs) ke saath cap karo. 8-10% achievable hai, lekin EPS recovery aur execution pe depend&mdash;quarterly reports dekho. Risk EPS decline continue hone ka hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Guide&apos;s Explanation:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Healthcare demand aur export push se growth promising hai, Jhunjhunwala ka sweet spot. Risks manage karne honge&mdash;aap isse growth story maante ho? EPS recovery aur regulations bade risks hain.</span></p>
<h4><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">7. Kya galat ho sakta hai?</span></strong></h4>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Business Risks:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Regulatory price caps revenue ko hit kar sakte hain. Generic competition market share chura sakta hai. API cost spikes operations ko hurt kar sakte hain. Export market disruptions (e.g., trade restrictions) revenue ko impact kar sakte hain. Market dip Albert David ko stall kar sakta hai.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Business Risks:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Price caps NPPA policies se ho sakte hain. Competition market dynamics se hai. API costs supply chain issues se hain.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Financial Risks:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Negative EPS growth (-38.9%), low OPM (11.2%), aur small market cap (₹486.1 crore) scalability dikhate hain. Moderate OCF (₹45.5 crore) growth dependence dikhata hai. Ye leaks hain&mdash;strong profit growth ke bawajood EPS issues downturn mein problem ban sakte hain. Jhunjhunwala cash aur earnings dekhta tha.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Financial Risks:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;EPS decline one-time costs se ho sakta hai. Low OPM pricing pressures se hai. Small scale market risks se hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Economic Risks:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Global slowdown export demand kam kar sakta hai. Rupee volatility export revenues pe asar daal sakti hai. Economic shifts wildcards hain&mdash;export trends matter karte hain.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Economic Risks:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Slowdown global recession se ho sakta hai. Rupee volatility forex markets se aa sakti hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Other Risks:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">New regulations (e.g., quality compliance) costs badha sakte hain. Supply chain disruptions (e.g., API shortages) production ko hurt kar sakte hain. Regulation hidden traps hain&mdash;Jhunjhunwala inko mitigate karta tha.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Other Risks:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Regulations DCGI norms se aa sakte hain. Disruptions global supply chains se hain.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Guide&apos;s Explanation:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Risks storm clouds hain&mdash;EPS decline, regulations, competition stand out. Jhunjhunwala inka weight karta&mdash;ye manageable lagta hai? EPS recovery aur regulatory risks bade concerns hain.</span></p>
<h4><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">8. Stock price kyun upar ja sakta hai?</span></strong></h4>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kya Madad Karega?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">EPS recovery revenue aur profits boost kar sakti hai. New product launches (e.g., generics, IV fluids) investor confidence badha sakte hain. Export market expansion margins badha sakta hai. Healthcare demand growth orders boost kar sakta hai. Ye triggers stock price lift kar sakte hain&mdash;Jhunjhunwala aise events pe entry time karta. EPS growth bada factor hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kab?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">1-2 saal mein play out ho sakta hai agar EPS recover kare aur export volumes badhein. 1-2 saal ka horizon value-growth play ke liye fit hai&mdash;patience chahiye.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Guide&apos;s Explanation:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Catalysts price lift kar sakte hain&mdash;Jhunjhunwala momentum ka wait karta. Ye timeline suitable hai? Risks manage karna zaroori hai.</span></p>
<h4><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">9. Kyun khareedna chahiye?</span></strong></h4>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kyun Invest Karein?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">~47.2% below ₹1,611.7 IV, P/E 12, 108.5% net profit growth, Piotroski Score 6&mdash;classic value play. OCF ₹45.5 crore aur low debt (0.01) rock-solid hain. Ye value stock with growth&mdash;Jhunjhunwala ka ideal. Numbers opportunity chillate hain. Risk EPS decline hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kyun Abhi?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">₹851.7 pe undervalued hai, at 51.44% fall from 52-week high, healthcare demand boom ahead hai. Abhi khareedna wave pakadna hai&mdash;Jhunjhunwala early strike karta. Risk further correction ka hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kitna?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Portfolio ka 1-3% risk aur reward balance ke liye. Chhota stake downside limit karta hai, Jhunjhunwala tactic. Risk nahi hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Guide&apos;s Explanation:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Value hybrid&mdash;Jhunjhunwala isse pasand karta with caution. Ye thesis click karta hai? EPS decline aur regulatory risks hain.</span></p>
<h4><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">10. Kya karna chahiye?</span></strong></h4>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Decision:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Buy.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kyun?:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Undervalued with growth potential.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Kab?:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Abhi; ₹750-800 pe dip aaye toh add karo.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Check On It:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Quarterly EPS, OCF, regulatory updates review karo.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Sell:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;₹1,611.7 (IV ke paas) ya agar EPS decline continue ho ya regulations revenue hit karein.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Jhunjhunwala Kaise Adjust Karta Tha?:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Fundamentals monitor karta, sustained EPS decline pe bech deta. Target price ₹1,611.7 pe profits lock karta. Overvaluation ya regulatory shocks pe positions kam karta. Profits doosre undervalued stocks mein lagata.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Example:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Albert David ke liye, Q4 FY25 mein EPS growth -20% ho toh 50% bech deta, baki recovery ke liye hold karta. OCF ₹40 crore+ rahe toh ₹750-800 pe add karta. Ye disciplined plan hai&mdash;Jhunjhunwala clear targets set karta. Risks badhe toh adjust karo. Risk nahi hai agar plan follow karo.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Guide&apos;s Explanation:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Structured approach&mdash;Jhunjhunwala isse follow karta. Ye actionable lagta hai? EPS aur OCF pe nazar rakho.</span></p>
<h4><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">11. Aur kya sochna hai?</span></strong></h4>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Log Kya Kehte Hain?</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">X pe sentiments mixed hain. Kai investors Albert David ko undervalued (P/E 12, 47.2% below IV) aur strong OCF growth (332.7%) ke liye value play maante hain, especially healthcare demand ke context mein. Lekin negative EPS growth (-38.9%) aur 51.44% fall from 52-week high pe concerns hain, kuch kehte hain ye one-time costs ya regulatory issues ka result hai.&nbsp;</span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Concerns:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;EPS decline shayad R&amp;D costs ya price controls se ho. Mixed views hain&mdash;Jhunjhunwala noise ignore karke data pe focus karta. Tum kya sochte ho&mdash;sentiments ya data zyada matter karta hai?</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Price Trend:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">51.44% fall from 52-week high dikhata hai stock adjust ho raha hai, dip pe buy ka mauka hai.&nbsp;</span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Price Fall:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Negative EPS growth, regulatory concerns, ya market sell-off se confidence dabaya ho sakta hai. Momentum shift ho sakta hai&mdash;pullback ka wait karo ya abhi chhoti position lo.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Stock Kaise Manage Karein:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;₹750-800 pe alerts set karo, volume aur regulatory news track karo.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">PEG Ratio:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">PEG TTM -0.3 (negative due to negative EPS growth), valuation unclear. Negative PEG growth concerns dikhata hai&mdash;Jhunjhunwala positive PEG &lt;1 prefer karta. Risk EPS recovery na hone ka hai.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Stock Kaise Manage Karein:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Q4 FY25 mein EPS growth check karo, positive PEG ho toh hold karo.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Guide&apos;s Explanation:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Data case support karta hai&mdash;undervaluation aur OCF strong. Lekin EPS decline aur regulatory risks concerns hain. Jhunjhunwala data pe focus karta&mdash;convinced ho? EPS recovery aur regulations pe dhyan dena chahiye.</span></p>
<h4><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">12. Investment wisdom ke saath kaise fit hai?</span></strong></h4>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Good Points:</span></strong></p>
<ul>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Benjamin Graham (Value Investing):</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Low P/E (12), P/B (1.2), aur 47.2% below IV margin of safety dete hain, Graham ka undervaluation principle.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Warren Buffett (Moat):</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Albert David ka niche IV fluids portfolio aur low debt ek moat hain, lekin small scale se weaken ho sakta hai.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Peter Lynch (Know What You Own):</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Pharma sector aur Albert David ka role simple aur predictable hai, Lynch ke &ldquo;invest in what you understand&rdquo; se fit.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><span style="font-size:11pt;font-family:Arial,sans-serif;">Classic value investing se align&mdash;Jhunjhunwala ka playbook, undervalued stocks with strong fundamentals.</span></p>
    </li>
</ul>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Challenges:</span></strong></p>
<ul>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Graham (Earnings Risks):</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Negative EPS growth (-38.9%) volatility dikhata hai, Graham caution karta tha aisi companies ke liye.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Buffett (Efficiency):</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Low OPM (11.2%) efficiency mein kami dikhata hai, Buffett high margins pasand karta.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Lynch (Growth):</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Negative EPS growth growth concerns raise karta hai, Lynch growth at reasonable price (GARP) prefer karta.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Challenges:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;EPS decline one-time costs se ho sakta hai. Low OPM pricing pressures se hai. Small scale market risks se hai. Flaws hain&mdash;EPS recovery ke liye adapt karna zaroori hai.</span></p>
    </li>
</ul>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Guide&apos;s Explanation:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Wisdom se align&mdash;value aur profitability strong, Jhunjhunwala flaws aur potential balance karta. Ye goals se fit hai? EPS decline aur OPM risks hain.</span></p>
<h4><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">13. Rakesh Jhunjhunwala ka approach kya kehta hai?</span></strong></h4>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Sustainability (OCF / Market Cap &times; 100):</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">₹45.5 crore / ₹486.1 crore = ~9.4%, Jhunjhunwala ke 3% threshold se upar. Decent sustainability&mdash;cash flow market cap ka significant hissa cover karta hai. Jhunjhunwala strong cash flow chahta tha&mdash;green light. Risk nahi hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Debt-to-OCF (OCF_Debt_Breaker):</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">0, negligible debt ke wajah se. Debt servicing capacity exceptional hai, debt-to-equity 0.01 isko support karta hai. Risk nahi hai.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Zero Ratio:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;No debt obligations strong financials dikhate hain.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Cash Conversion Efficiency (CCE):</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">60.3%, profit to cash conversion moderate. Decent CCE efficiency dikhata hai&mdash;Jhunjhunwala higher conversion chahta tha. Risk OCF slow hone ka hai.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Moderate CCE:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;OCF growth strong lekin profit base chhota hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">P/E Ratio:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">12, Jhunjhunwala ke 15 threshold se neeche. Buy signal&mdash;undervaluation clear hai. Risk EPS decline ka ho sakta hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Moat:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Albert David ka moat niche products, low debt, aur promoter backing pe hai, lekin small scale aur regulatory dependence se weak. Modest moat&mdash;Jhunjhunwala innovation pe push karta. Risk regulatory shocks ya competitors ke aage nikalne ka hai.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Weak Moat:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Small scale market share limit karta hai. Regulatory dependence price caps se hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Cash Flow Fix? Specific Numbers Ke Saath Clarity:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">OCF ₹45.5 crore aur net cash ₹4 crore stable hain, lekin EPS growth fix karna zaroori hai.&nbsp;</span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Target EPS Growth:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Positive ho ya -10% tak (Q4 FY25).&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Free Cash Flow:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;FCF (OCF - CapEx) calculate karo, investments ke baad cash bachta hai ya nahi.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Actionable Steps:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Q4 FY25 mein EPS growth positive ho toh buy/hold karo. EPS -20% ho toh partial stakes becho. Jhunjhunwala do quarters ke improved earnings ka wait karta tha. EPS recovery pe focus chahiye. Risk EPS decline continue hone ka hai.&nbsp;</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reason for Fix Needed:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Negative EPS one-time costs ya pricing issues se ho sakta hai.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Guide&apos;s Explanation:</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Jhunjhunwala ko low P/E, decent CCE, aur sustainability pasand hote, lekin EPS fix ka wait karta. Ye style se partial match karta hai? EPS decline aur regulatory risks bade concerns hain.</span></p>
<h4><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">14. Future Decisions Aur Approach (Board Meeting, Latest Available)</span></strong></h4>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Latest Available Board Meeting Details:</span></strong></p>
<ul>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Date of Latest Board Meeting:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;February 12, 2025</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Purpose:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Quarterly Results (Q3 FY25)</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Key Decisions and Outcomes:</span></strong></p>
        <ul>
            <li style="list-style-type:circle;font-size:11pt;font-family:Arial,sans-serif;">
                <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Financial Performance Review:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;The board reviewed the unaudited financial results for the quarter and nine months ended December 31, 2024. Albert David reported a consolidated loss of ₹9.39 crore on a total income of ₹74.08 crore for Q3 FY25, indicating a challenging quarter. This loss was primarily attributed to de-growth in the pharmaceutical and API sectors, potentially due to pricing pressures or one-time costs.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br><br></span></p>
            </li>
            <li style="list-style-type:circle;font-size:11pt;font-family:Arial,sans-serif;">
                <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Operational Updates:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;No specific operational decisions (e.g., new product launches, capacity expansions) were disclosed in the available announcements. The focus was on financial performance, suggesting a cautious approach amid market challenges.</span></p>
            </li>
            <li style="list-style-type:circle;font-size:11pt;font-family:Arial,sans-serif;">
                <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Regulatory Compliance:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;The board ensured compliance with SEBI regulations, including disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares &amp; Takeovers) Regulations, 2011, for Kothari Phytochemicals &amp; Industries Ltd., indicating transparency in shareholding changes.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br><br></span></p>
            </li>
            <li style="list-style-type:circle;font-size:11pt;font-family:Arial,sans-serif;">
                <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">No Dividend or Corporate Actions:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;No announcements regarding dividends, stock splits, or other corporate actions were made, aligning with the company&rsquo;s focus on reinvestment (low dividend payout ratio of 16.2%).</span></p>
            </li>
        </ul>
    </li>
</ul>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Other Recent Board-Related Announcements:</span></strong></p>
<ul>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Resignation of Director:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;On March 10, 2025, Mr. Shirish Gundopant Belapure resigned as an Independent Director, citing personal reasons. This change may impact board dynamics, but the company retains a balanced mix of executive and independent directors.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br><br></span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Committee Reconstitution (September 13, 2022):</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;While not recent, the board reconstituted the Stakeholder Relationship and Grievance Committee and Corporate Social Responsibility Committee in 2022, indicating a focus on governance and stakeholder engagement. No updates on further reconstitutions were available for 2025.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br><br></span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">AGM Outcomes (August 9, 2024):</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;The 86th Annual General Meeting approved all resolutions, including the financial statements for FY24, dividend of ₹11.5 per share (115%), and reappointment of directors. This reflects stable governance but no forward-looking strategic announcements.</span></p>
    </li>
</ul>
<p><br></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Future Approach Based on Available Data:</span></strong></p>
<ul>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Cost Management and Efficiency:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;The Q3 FY25 loss suggests the board may prioritize cost optimization and operational efficiency to counter pricing pressures and API cost volatility. The high operating cash flow growth (332.7% YoY) indicates efforts to improve collections or reduce working capital needs.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">EPS Recovery Focus:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Given the negative EPS growth (-38.9%), the board is likely to focus on stabilizing earnings through new product launches (e.g., specialty generics or IV fluids) or margin improvement in existing portfolios. Q4 FY25 results (expected May 2025) will be critical for assessing recovery.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Export Expansion:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;With ~20-25% revenue from exports, the board may push for deeper penetration in Africa, ASEAN, and Latin America to diversify revenue and offset domestic regulatory risks. Strategic partnerships or R&amp;D collaborations (e.g., with Indian Institute of Chemical Biology) could be emphasized.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Regulatory Navigation:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;The board&rsquo;s adherence to SEBI and MCA regulations (e.g., cost auditor appointment for FY25, independent director compliance) suggests a proactive approach to managing regulatory risks, especially NPPA price caps or DCGI quality norms.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Reinvestment Strategy:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;The low dividend payout ratio (16.2%) and moderate capex indicate a focus on reinvesting profits into R&amp;D or export infrastructure. The board may announce capacity expansions or new product pipelines in FY26, depending on cash flow stability (OCF ₹45.5 crore, net cash ₹4 crore).</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Board Stability:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Post-resignation, the board (led by A. K. Kothari and Umesh Manohar Kunte) is expected to maintain governance standards, with potential new independent director appointments by Q4 FY25 to ensure diversity and expertise.</span></p>
    </li>
</ul>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Anticipated Future Board Meetings:</span></strong></p>
<ul>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Q4 FY25 Results (May 2025):</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Expected to review full-year performance, EPS recovery, and cash flow trends. Potential announcements on dividends or strategic initiatives (e.g., R&amp;D investments, export contracts).</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">AGM 2025 (August 2025):</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Likely to approve FY25 financials, director reappointments, and any new corporate actions. Strategic updates on product pipelines or market expansion may be shared.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Ad-Hoc Meetings:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Possible meetings in Q1 FY26 to address regulatory changes (e.g., NPPA price revisions) or significant export orders, given the company&rsquo;s export focus.</span></p>
    </li>
</ul>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Risks and Considerations:</span></strong></p>
<ul>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><span style="font-size:11pt;font-family:Arial,sans-serif;">The Q3 FY25 loss and negative EPS growth highlight earnings volatility, which the board must address to restore investor confidence.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><span style="font-size:11pt;font-family:Arial,sans-serif;"><span style="border:none;"><img src="%20" width="16" height="16"></span></span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><span style="font-size:11pt;font-family:Arial,sans-serif;">Regulatory pressures (e.g., price caps, quality compliance) could delay recovery, requiring proactive lobbying or cost adjustments.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><span style="font-size:11pt;font-family:Arial,sans-serif;">Limited disclosures on strategic plans (e.g., new products, capex) make it challenging to predict aggressive growth moves. Investors should monitor management commentary in Q4 FY25 results.</span></p>
    </li>
</ul>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Guide&rsquo;s Explanation:</span></strong></p>
<p><span style="font-size:11pt;font-family:Arial,sans-serif;">The board&rsquo;s recent focus has been on financial review and compliance, with no major strategic announcements post-Q3 FY25 loss. Jhunjhunwala would urge caution until EPS recovery is visible, emphasizing OCF and regulatory updates. The approach seems defensive&mdash;cost control and export focus&mdash;but lacks bold growth signals. Aapko lagta hai board EPS fix karega ya conservative rahega? Q4 FY25 results aur regulatory news pe nazar rakhein.</span></p>
<h4><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">15. Future mein important dates kya hain?</span></strong></h4>
<ul>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Q4 FY25 Results:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;May 2025 ke aaspaas&mdash;EPS, OCF, revenue trends ke liye critical.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Regulatory Updates:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;DCGI/NPPA announcements, June 2025 tak monitor karo (e.g., price caps, quality norms).</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Annual Report FY25:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;September 2025 tak&mdash;R&amp;D, export plans, strategic goals ki details.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Healthcare Policy Updates:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;2025-26 budget, Feb 2025, healthcare demand ke liye.</span></p>
    </li>
    <li style="list-style-type:disc;font-size:11pt;font-family:Arial,sans-serif;">
        <p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Export Market Trends:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;2025 mein updates jo export orders ya currency fluctuations pe asar daal sake.</span><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span><span style="font-size:11pt;font-family:Arial,sans-serif;">Ye dates thesis validate karne ke checkpoints hain&mdash;Jhunjhunwala milestones track karta positions adjust karne ke liye. Risk nahi hai.</span></p>
    </li>
</ul>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Final Thoughts (Bottom Line)</span></strong><strong><span style="font-size:11pt;font-family:Arial,sans-serif;"><br></span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Albert David Limited ek compelling value investment hai&mdash;~47.2% below ₹1,611.7 IV, P/E 12, 108.5% net profit growth, Piotroski Score 6. High OCF growth (332.7%), low debt (0.01), aur ROE 19.7% solid hain, lekin negative EPS growth (-38.9%), low OPM (11.2%), aur 51.44% price fall concerns hain. ₹851.7 pe, 1-3% portfolio allocation ₹1,611.7 target karta hai, pharma sector ke growth ke saath. Kothari family ka promoter backing Jhunjhunwala ke lens se align hai, lekin EPS, OCF, aur regulations monitor karo. Graham ke value aur Buffett ke moat principles se fit hai&mdash;quarterly review aur plan follow karo.</span></p>
<p><strong><span style="font-size:11pt;font-family:Arial,sans-serif;">Note:</span></strong><span style="font-size:11pt;font-family:Arial,sans-serif;">&nbsp;Negative EPS growth (-38.9%) and 51.44% price fall raise concerns about earnings stability.</span></p>
<p><br></p>
<p><br></p>
<p><br></p>
<p><br></p>
<p><br></p>
<div align="left">
    <table style="border: none; border-collapse: collapse; width: 100%;">
        <tbody>
            <tr>
                <td colspan="4" style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><strong><span style="font-size:11pt;font-family:Calibri,sans-serif;">Healthcare &amp; Biotech</span></strong></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><strong><span style="font-size:11pt;font-family:Calibri,sans-serif;">Metric</span></strong></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><strong><span style="font-size:11pt;font-family:Calibri,sans-serif;">Range</span></strong></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><strong><span style="font-size:11pt;font-family:Calibri,sans-serif;">Current</span></strong></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><strong><span style="font-size:11pt;font-family:Calibri,sans-serif;">Why It Matters</span></strong></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">ROE Ann. %</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&gt;15%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">19.7%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Shows good profit from invested money (e.g., Sun Pharma).</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Piotroski Score</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&ge;7</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">6</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Ensures the company is financially healthy despite risks.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">PE TTM</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&lt;30</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">11.7</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Stock price should be fair for earnings in pharma/biotech.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Rev. Growth Ann. YOY %</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&gt;15%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">17.7%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Sales growth is key for new drugs (e.g., Dr. Reddy&rsquo;s).</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Net Profit Growth YOY %</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&gt;12%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">108.5%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Steady profit growth supports drug development.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Debt-to-Equity</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&lt;0.7</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">0.01</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Moderate debt allows funding for trials (e.g., Biocon).</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Price_to_IV_Distance</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&lt;-15%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">-48.8</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Stock should be at least 15% cheaper than its true value with growth room.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">ROIC Ann. %</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&gt;12%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">19.6%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Shows efficient use of money for drug approvals.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Net Cash Flow Ann.</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&gt;0</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">4</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Cash supports research (e.g., Cipla).</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">PEG TTM</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&lt;1.5</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">-0.3</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Balances stock price with growth in new treatments.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Market Cap</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&gt;5000 Cr</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">471.3 Cr</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Medium and big companies balance stability and new ideas.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Dividend Yield 3YR %</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&gt;1%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">1.2%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Dividends common in pharma, optional in biotech.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Promoter Holding %</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&gt;40%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">62.24%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Founders with big stakes show dedication (e.g., Lupin).</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Price to Book</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&lt;3.5</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">1.1</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Stock price reflects value of drug patents.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Cash from Operating Act.</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">Moderate</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">45.5</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Steady cash in generics, less in biotech due to trials.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Operating Margin %</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&gt;18%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">11.2</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">High profits from drug sales show efficiency.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Free Cash Flow</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&gt;0</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">-</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Extra cash funds clinical trials.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Dividend Payout Ratio</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&lt;40%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">16.2%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Balances dividends with research spending.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Interest Coverage Ratio</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&gt;3</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">325.1</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Paying debt easily reduces risk in biotech.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Revenue Growth 3YR CAGR</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&gt;12%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">-</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Growing sales due to aging population.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Sustainability Ratio</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&gt;2.5%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">9.7</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Cash ensures long-term research success.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Debt to OCF Ratio</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&lt;2.5</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">0</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Low debt compared to cash flow keeps flexibility.</span></p>
                </td>
            </tr>
            <tr>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Cash Conversion Efficiency</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">&gt;85%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p style="text-align: center;"><span style="font-size:11pt;font-family:Calibri,sans-serif;">60.3%</span></p>
                </td>
                <td style="border: solid #000000 0.68181825pt;">
                    <p><span style="font-size:11pt;font-family:Calibri,sans-serif;">Real profits avoid fake earnings in biotech.</span></p>
                </td>
            </tr>
        </tbody>
    </table>
</div>
<p><br></p>
<p><br></p>
